

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Isodiol International (the "Issuer" or "Isodiol").

Trading Symbol: ISOL

Number of Outstanding Listed Securities: 217,994,382

Date: October 6, 2017

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

Isodiol is a product development, sales, marketing and distribution company for hemp-based products and solutions, including Hemp-derived cannabidiol (CBD). The Issuer specializes in identifying emerging trends and opportunities such as CBD, one of the most useful compounds found in the hemp plant. Hemp is recognized as a superfood and its use in health and functional foods is growing. The Issuer works with manufacturers and suppliers to develop nutritional hemp-based products, including functional beverages specifically for the Issuer, which provides high levels of protein and/or nutrition, and then arranges for the sale and distribution of these products.

The Issuer issued 6,844,079 common shares during the month of August.

2. Provide a general overview and discussion of the activities of management.

Management continues to work toward developing the Issuer's business as described under Item 1 above. Management is focused on increasing sales in the wholly-owned subsidiary, ISO International, LLC and continues to look for other strategic business relationships.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

During the month of September, the Company announced it will be launching a new phytochemical division that will focus on cannabinoids and terpenes derived from non-cannabis sources. The Company has also formed IsoLabs International, a new division that will focus in the licensed medical marijuana markets in both North America and abroad. IsoLabs will process and manufacture medical cannabis products within approved jurisdictions.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

N/A

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

The Company named North 6th Agency (N6A) as the company's public relations agency of record (AOR).

Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

N/A

6. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

N/A

7. Describe the acquisition of new customers or loss of customers.

N/A

8. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.

N/A

9. Report on any employee hiring's, terminations or lay-offs with details of anticipated length of lay-offs.

N/A

10. Report on any labour disputes and resolutions of those disputes if applicable.

N/A

11. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

N/A

12. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

N/A

13. Provide details of any securities issued and options or warrants granted.

Date	Transaction	No. of Shares	Price per Share	No. of Warrants or Options	Warrant or Option Exercise Price	Warrant Expiry Date
September 1, 2017	Grant of options	N/A	N/A	5,000,000	\$0.315	N/A
September 8, 2017	Exercise of warrants	66,666	N/A	N/A	\$0.25	N/A
September 8, 2017	Exercise of options	300,000	N/A	N/A	\$0.16	N/A
September 12, 2017	Private Placement	4,012,414	\$0.25	4,012,414	\$0.75	N/A
September 12, 2017	Shares issued for services	2,333,333	\$0.22	N/A	N/A	N/A
September 25, 2017	Exercise of Warrants	131,666	N/A	N/A	\$0.25	N/A

14. Provide details of any loans to or by Related Persons.

N/A

15. Provide details of any changes in directors, officers or committee members.

N/A

16. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The trends and risks which are likely to impact the Issuer are detailed in the Issuer's Form 2A Listing Statement dated August 31, 2015 (the "Listing Statement") under the heading "Item 17. Risk Factors". The Listing Statement was posted on the CSE website on September 2, 2015.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated October 6, 2017

Bryan Loree

Name of Director or Senior Officer

"Bryan Loree"

Signature

Director & CFO

Official Capacity

<i>Issuer Details</i> Name of Issuer Isodiol International Inc.	For Month End September, 2017	Date of Report YY/MM/DD 2017/10/06
Issuer Address 1212 Austin Ave, Coquitlam, BC V3K 3P5	Issuer Fax No. 604 637 5624	Issuer Telephone No. c/o 604-808-2225
Contact Name Bryan Loree	Contact Position Director and CFO	Contact Telephone No. 604-808-2225
Contact Email Address bryan@isodiol.com	Web Site Address www.isodiol.com	